Nasdaq rxrx

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.9% on Insider Selling marketbeat.com - December 29 at 10:20 AM: Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock marketbeat.com - December 28 at 6:33 PM.

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues Dec 09. Co-Founder notifies of intention to sell stock Dec 08. Chief Financial Officer exercised options and sold US$266k worth of stock Nov 19. Consensus EPS estimates fall by 18% Nov 16.Key statistics. On Friday, Recursion Pharmaceuticals Inc (RXRX:NSQ) closed at 11.16, -33.35% below its 52-week high of 16.75, set on Jul 19, 2023. Data delayed at least 15 minutes, as of Jan 12 2024 21:00 GMT. Latest Recursion Pharmaceuticals Inc (RXRX:NSQ) share price with interactive charts, historical prices, comparative analysis, …

Did you know?

So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ...Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...Recurson Pharmaceuticals (NASDAQ:RXRX) – Purchased 219,586 shares through ARK Genomic Revolution ETF (BATS:ARKG). Ginkgo Bioworks Holdings Inc (NASDAQ:DNA) – Purchased a combined total of ...

The idea of Recursion Pharmaceuticals (RXRX-4.65%) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify ...Recurson Pharmaceuticals (NASDAQ:RXRX) – Purchased 219,586 shares through ARK Genomic Revolution ETF (BATS:ARKG). Ginkgo Bioworks Holdings Inc (NASDAQ:DNA) – Purchased a combined total of ...Jul 13, 2023 · Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ... 5 days ago · RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Jan 26, 2024 4:03 p.m. EST Delayed quote $ 9.87 0.09 0.92% After Hours... 2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ...

Dec 16, 2023 · Recursion Pharmaceuticals (NASDAQ: RXRX) has built one of the world’s most advanced AI-powered platforms to help decode human biology. RXRX gathers data and experiments on millions of biological ... Find the latest analyst research for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. ... Based on analysts offering 12 month price targets for RXRX in the last 3 months. SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ... ….

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Nasdaq rxrx. Possible cause: Not clear nasdaq rxrx.

Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.An analysis of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock in terms of its daily trading volume indicates that the 3-month average is 4.10 million. However, this figure increases on the past 10-day timeline to an average of 4.76 million. Current records show that the company has 183.21M in outstanding shares.Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» …

For a biotech like Recursion Pharmaceuticals (RXRX-1.25%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues Dec 09. Co-Founder notifies of intention to sell stock Dec 08. Chief Financial Officer exercised options and sold US$266k worth of stock Nov 19. Consensus EPS estimates fall by 18% Nov 16.

2 bedroom apartments with washer and dryer in unit near me Nov 10, 2023 · With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) may be sending very bearish signals at the moment, given that almost half of all the Biotechs ... Stock. Equities. Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ): Stock quote, stock chart, quotes, analysis, … mauston opercent27reillypercent27ssks msra jdyd Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 320.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission.The institutional investor owned 3,523,124 shares of the company's stock … sksy sn bala Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities). spend all of elon muskzavarellinoel palomera vasquez Jul 18, 2023 · After announcing that it would get a $50 million investment from NVIDIA (NVDA 0.27%) on July 12, Recursion Pharmaceuticals (RXRX 8.83%) saw its stock blast off, rising 87% over the following two ... 5 dollar popeyes dollar5 box See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. dark web communitieswal mart 306 supercenter directoryhab Dec 16, 2023 · Recursion Pharmaceuticals (NASDAQ: RXRX) has built one of the world’s most advanced AI-powered platforms to help decode human biology. RXRX gathers data and experiments on millions of biological ... PTC Therapeutics (NASDAQ:PTCT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the better investment?We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, …